A Chinese study of 174 stage III melanoma patients, 67.7% (n = 118) of whom were of the AM subtype, reported that anti-PD-1 adjuvant therapy improved disease-free survival (DFS) compared to HD-IFN or observation-only treatment in the overall cohort (p = 0.039) [111]. This evidence concerns the gene IFNA1 and melanoma.